# Health<sup>™</sup>

## **Journal Articles**

2020

# Comparison of Clinical and Epidemiologic Characteristics of Young Febrile Infants with and without SARS-CoV-2 Infection.

J. Leibowitz Zucker School of Medicine at Hofstra/Northwell

W. Krief Zucker School of Medicine at Hofstra/Northwell

S. Barone Zucker School of Medicine at Hofstra/Northwell

K. A. Williamson Zucker School of Medicine at Hofstra/Northwell

P. Goenka Zucker School of Medicine at Hofstra/Northwell

See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/publications

Part of the Pediatrics Commons

# **Recommended Citation**

Leibowitz J, Krief W, Barone S, Williamson KA, Goenka P, Rai S, Moriarty S, Baodhankar P, Rubin LG. Comparison of Clinical and Epidemiologic Characteristics of Young Febrile Infants with and without SARS-CoV-2 Infection... 2020 Jan 01; ():Article 6743 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/publications/6743. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

# Authors

J. Leibowitz, W. Krief, S. Barone, K. A. Williamson, P. Goenka, S. Rai, S. Moriarty, P. Baodhankar, and L. G. Rubin



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Journal Pre-proof

Comparison of Clinical and Epidemiologic Characteristics of Young Febrile Infants with and without SARS-CoV-2 Infection

Jill Leibowitz, MD, William Krief, MD, Stephen Barone, MD, Kristy A. Williamson, MD, Pratichi K. Goenka, MD, Shipra Rai, MD MPH, Shannon Moriarty, DO MS, Prachi Baodhankar, MD, Lorry G. Rubin, MD

PII: S0022-3476(20)31264-6

DOI: https://doi.org/10.1016/j.jpeds.2020.10.002

Reference: YMPD 11822

To appear in: The Journal of Pediatrics

Received Date: 18 September 2020

Revised Date: 1 October 2020

Accepted Date: 2 October 2020

Please cite this article as: Leibowitz J, Krief W, Barone S, Williamson KA, Goenka PK, Rai S, Moriarty S, Baodhankar P, Rubin LG, Comparison of Clinical and Epidemiologic Characteristics of Young Febrile Infants with and without SARS-CoV-2 Infection, *The Journal of Pediatrics* (2020), doi: https://doi.org/10.1016/j.jpeds.2020.10.002.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Elsevier Inc. All rights reserved.



**Title:** Comparison of Clinical and Epidemiologic Characteristics of Young Febrile Infants with and without SARS-CoV-2 Infection

Jill Leibowitz MD<sup>1,2</sup>, William Krief MD<sup>1,2</sup>, Stephen Barone MD<sup>1,2</sup>, Kristy A. Williamson MD<sup>1,2</sup>,

Pratichi K. Goenka MD<sup>1,2</sup>, Shipra Rai MD MPH<sup>1</sup>, Shannon Moriarty DO MS<sup>1</sup>,

Prachi Baodhankar MD<sup>1</sup>, Lorry G. Rubin MD<sup>1,2</sup>

Affiliations: <sup>1</sup>Department of Pediatrics, Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY

<sup>2</sup>Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health,

Hempstead, NY

**Corresponding Author:** Jill Leibowitz, Cohen Children's Medical Center, Division of Pediatric Hospital Medicine, 269-01 76<sup>th</sup> Avenue, New Hyde Park, NY,

11040, Jleibowitz@northwell.edu, Phone number: 718-470-3324, Fax number: 718-347-0468

**Reprint Request Author:** Jill Leibowitz

Key Words: SARS-CoV-2, pandemic, serious bacterial infection

The authors declare no conflicts of interest.

List of Abbreviations: Novel Coronavirus 2019 (COVID-19), respiratory viral panel

(RVP), United States (US), Cohen Children's Medical Center (CCMC), emergency department

(ED), nucleic acid amplification (NAA), pediatric intensive care unit (PICU), absolute neutrophil

count (ANC), absolute lymphocyte count (ALC) white blood cell count (WBC)

**Objective**: To determine features that distinguish febrile young infants with SARS-CoV-2 infection.

**Study design:** Retrospective single-center study included febrile infants <57 days evaluated in the Emergency Department of Cohen Children's Medical Center of Northwell Health, New Hyde Park, New York during March 1-April 30 of 2018, 2019, and 2020. Sociodemographic and clinical features were compared between those seen during the 2020 COVID-19 pandemic and previous years, as well as between SARS-CoV-2 infected infants and SARS-CoV-2 uninfected infants (SARS-CoV-2 negative or evaluated during 2018 and 2019).

**Results:** In all, 124 febrile infants <57 days of age were identified; 38 during the 2-month study period in 2018, 33 in 2019, and 53 in 2020. During 2020, fewer febrile infants had a serious bacterial infection (SBI) or a positive respiratory viral panel (RVP) than in prior years (6% versus 21%, P = .02; 15% versus 53%, p<.001, respectively). SARS-CoV-2 was the most frequent pathogen detected in 2020; of 30 infants tested, 20 tested positive. Infants with SARS-CoV-2 were more likely to identify as Hispanic (p=.004), have public insurance or were uninsured (p=.01), exhibited lethargy (p=.02), had feeding difficulties (p=.002), and had lower white blood cell (p=.001), neutrophil (p<.001), and lymphocyte counts (p=.005) than the 81 infants without SARS-CoV-2 infection. None of the infants with SARS-CoV-2 had concurrent SBI or detection of another virus. Overall, disease in infants with SARS-CoV-2 was mild.

**Conclusions:** During the peak of the pandemic, SARS-CoV-2 was the predominant pathogen among febrile infants. Socioeconomic, historical, and laboratory features differed significantly between SARS-CoV-2 infected and uninfected infants. None of the 20 infants with SARS-CoV-2 infection had an identified co-viral or serious bacterial infection.

Page 3

The first case of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),was diagnosed in December of 2019 in Wuhan, China and was designated as a worldwide pandemic in March 2020.<sup>1,2</sup> In January 2020,

the first case in the United States (US) was identified, and in March 2020 a national emergency was declared.<sup>3</sup> Based on data from the Centers for Disease Control and Prevention through July 2020, infants < 3 months of age accounted for 18.8% of hospitalized pediatric COVID-19 patients in the US, and children younger than one year of age accounted for 10% of fatalities associated with SARS-CoV-2 in US children, however, the proportion of children younger than 2-3 months of age was not specified.<sup>4,5</sup> Although an early study from Wuhan, China reported 10.6% of COVID-19 cases in children less than one year of age to be critical or severe, of these cases, not all were laboratory confirmed SARS-CoV-2 infection and other viral etiologies of illness were not excluded.<sup>6</sup> Since then, a number of case reports and small series describing infants less than 2 months of age have been published, most reporting mild disease, with many infants coming to medical attention due to fever, lethargy and poor feeding, but without respiratory manifestations as seen in adult patients.<sup>7,8,9,10,11,12,13</sup> The largest case series to date describes 18 infants younger than 90 days of age who tested positive for SARS-CoV-2, 14 of whom were febrile.<sup>9</sup>

The objective of this study was to compare the clinical and demographic characteristics and hospital course of febrile infants who presented to Cohen Children's Medical Center (CCMC) during March and April of 2020, the time period of peak COVID-19 incidence in our region, to febrile infants treated in CCMC during March and April of previous years.<sup>14</sup> Particular emphasis was placed on infants in whom SARS-CoV-2 was detected in order to provide relevant clinical data for clinicians evaluating infants with fever during the pandemic.

#### Methods

Page 4

#### **Study Design and Population**

We conducted a single centered, retrospective study of febrile infants evaluated in the Emergency Department of Cohen Children's Medical Center (CCMC) of Northwell Health (New Hyde Park, NY) who were < 57 days of age who had a documented temperature of  $\geq 38^{\circ}$ C at home or in the Emergency Department (ED) within the previous 24 hours and were treated at CCMC during the initial COVID-19 pandemic period (March 1, 2020- April 30, 2020) or during the corresponding months in the previous two years (March 1, 2018- April 30, 2018, March 1, 2019- April 30, 2019). CCMC is located at the border of Nassau County and Queens in New York, which was the epicenter of COVID-19 in the US during the study period. The investigation included both infants who were evaluated and discharged from the CCMC ED and those admitted to an inpatient unit. Per institutional policy, all febrile infants < 28 days are hospitalized, but for infants 29-56 days of age a decision to hospitalize is based on clinical criteria. For infants with an ED revisit or readmission to CCMC within 7 days, only the first visit was included in the study.

# **SARS-CoV-2** Testing

Patients were classified as having SARS-CoV-2 when a nasopharyngeal or combined nasopharyngeal/oropharyngeal swab tested positive by one of several nucleic acid amplification (NAA) assays for SARS-CoV-2 in Northwell Health Laboratories. As of March 24, 2020 all infants admitted to CCMC underwent SARS-CoV-2 testing but prior to March 24, testing for SARS-CoV-2 was not universal because of limited testing capacity. During the study period SARS-CoV-2 testing of febrile infants who were discharged from the emergency department was not universally applied.

#### **Study Variables**

Cases were ascertained through review of ICD-10 billing codes and discharge diagnosis in the electronic medical record. Clinical, laboratory and sociodemographic data were abstracted from the electronic health record and managed with the use of a REDCap electronic database.<sup>15</sup> Collected data included age, sex, ethnicity, race, primary language, insurance, length of hospital stay, history of sick contacts or known COVID-19 exposure, history of prematurity or underlying medical condition, disposition from the ED (discharged home versus hospital admission), and need for admission to the pediatric intensive care unit (PICU). The presence or absence of symptoms such as fever, cough, rhinorrhea, feeding difficulties (defined as decreased oral intake), emesis, diarrhea, irritability, lethargy and rash, and vital signs and ascultatory lung examination were also recorded. Laboratory results included SARS-CoV-2 NAA assays test results, complete blood count (CBC) and white blood cell differential, urinalysis, hepatic assays, cerebrospinal fluid parameters, bacterial cultures (urine, blood, cerebrospinal fluid), respiratory viral panel (RVP); GenMark Diagnostics, Carlsbad, CA), erythrocyte sedimentation rate and C-reactive protein, stool assays (stool culture, rotavirus antigen, multiple pathogen gastrointestinal panel by NAA (GI NAA) assay, and herpes simplex virus (HSV) testing (NAA testing of cerebrospinal fluid, whole blood, surface specimens and vesicles). Days of antimicrobial therapy, measured from date of first to last dose, and type and duration of respiratory support (e.g., supplemental oxygen, non-invasive ventilation or mechanical ventilation), measured from date of initiation to discontinuation, were recorded. Neutropenia was defined as an absolute neutrophil count (ANC) of < 1000 cells/µL, lymphopenia was defined as an absolute lymphocyte count (ALC) of < 3000

cells/ $\mu$ L.<sup>16,17</sup> Serious bacterial infection was defined as the growth of a bacterial organism in the blood, urine, or cerebrospinal fluid that was deemed pathogenic.<sup>18,19</sup>

Febrile infants were classified based on the year of presentation (eg, 2018, 2019, 2020). Febrile infants were also categorized based on their SARS-CoV-2 status: (1) infants who were SARS-CoV-2 test positive during March-April 2020 were classified as SARS-CoV-2 infected; (2) infants who were treated between March and April 2020 but were not tested for SARS-CoV-2 were categorized as SARS-CoV-2 indeterminate; (3) infants who were SARS-CoV-2 negative during March-April 2020 and febrile infants treated during March-April of 2018 and 2019 were classified as SARS-CoV-2 uninfected. SARS-CoV-2 indeterminate infants were included in the analyses of the March-April 2020 cohort versus March-April 2018-2019 cohort but excluded from the analyses that compared SARS-CoV-2 infected and uninfected groups.

Sixteen of the SARS-CoV-2 infected infants were reported in previous studies.<sup>13,14</sup>

This study was approved by the Northwell Health Institutional Review Board.

#### **Statistical Analyses**

We categorized and analyzed the data according to the patients' SARS-CoV-2 status (infected or uninfected) and year of presentation. For purposes of analysis, we combined the 2018 and 2019 cohorts as a single cohort. We performed descriptive and bivariable analyses using Fisher exact test for categorical data, Student *t* test for continuous variables, and the Wilcoxon rank-sum test

for ordinal data. All tests of significance were 2-sided with an  $\alpha$  value of 0.05. Statistical analysis was performed by using SPSS 25 (IBM Corp, Armonk, NY).

#### Results

#### Characteristics of the overall study population

A total of 124 infants were identified and included in the study: 38 during March-

April 2018 (2018), 33 during March-April 2019 (2019), and 53 during March-April 2020 (2020). Overall, the age distribution was as follows: 12 (10%) were 0-14 days, 29 (23%) were 15-28 days, and 83 (67%) were 29-56 days; 69 (56%) were male; 80(65%) were admitted to general inpatient unit, 2 (2%) to the PICU, and 42 (34%) were discharged home from the ED. Patient demographics are summarized in **Table I**.

#### Comparison of 2020 cohort with 2018-2019 cohort

Compared with febrile infants presenting in 2018 and 2019, febrile infants in 2020 were similar in age and by sex, but were more likely to identify as Hispanic (p=.04) (**Table 1**). In 2020, there were significantly fewer infants with a SBI, as SBI was detected in three of 53 (6%) infants in 2020 compared with 15 of 71 (21%) in 2018-2019 (p=.02). The 3 infants with SBI in 2020 had a urinary tract infection and in 2018-2019, 11 (15%) infants had a urinary tract infection, 3 (4%) had a urinary tract infection with bacteremia, and 1 (1%) had bacteremia. One infant was treated for mastitis in 2018-2019. There were significantly fewer infants with a positive RVP in 2020 than during 2018-2019: 15% during 2020 and 53% during 2018-2019 (p <.001) (**Table 1**). Additional viral infections identified were 2 cases of rotavirus, one case each of enterovirus

meningitis and HSV meningitis in 2018-2019, and one case of meningitis with human herpes virus-6 detection in each of the 2018-2019 and in 2020 cohorts.

#### **Characteristics of SARS-CoV-2 infected infants**

Thirty of the infants evaluated in the ED in 2020 were tested for SARS-CoV-2; 20 (67%) tested positive (95% CI: 48.8%-80.8%) with 4/20 (20%) 0-14 days of age, 7 /20 (35%) 15-28 days of age, and 9/20 (45%) 29-56 days of age. Of these 20 infants, 15 (75%) were admitted to hospital including one who was admitted to the PICU due to a brief requirement for treatment with high flow oxygen by nasal cannula. One hospitalized infant with SARS-CoV-2 infection was readmitted, and another infant was discharged from the ED and subsequently admitted. Mean length of hospital stay for admitted patients was 53.4 hours (range of 42.2 hours to 96.3 hours).

#### Comparison of SARS-CoV-2 infected infants with SARS-CoV-2 uninfected infants

Demographic and clinical variables of 20 SARS-CoV-2 positive infants were compared with 81 uninfected infants (71 seen 2018 and 2019 and the 10 SARS-CoV-2 negative infants seen in 2020) (**Table 2** and Table **3**). A significantly higher proportion of infants in the COVID-19 group had public insurance or were uninsured and identified as Hispanic (p=.01 and p=.004, respectively). The racial distribution of the groups differed significantly with a higher proportion of patients identified as "multiracial/other" and a smaller proportion identified as Asian or Black in the SARS-CoV-2 group (p=.04). Infants with COVID-19 were significantly younger (p=.03), had a higher proportion with reported feeding difficulty (p=.002) and had a higher proportion with reported lethargy (p=.02) than the SARS-CoV-2 negative group. Infants

with COVID-19 had a significantly lower mean white blood cell count (WBC) (p=.001), mean ANC (p=<.001) and mean ALC (p=.005) than those who were SARS-CoV-2 uninfected. None of the infants with COVID-19 had a concurrent SBI (0% [95% CI:0-16.1]) or another respiratory viral infection compared with the SARS-CoV-2 uninfected infants in whom SBI and respiratory viral infection were detected in 22% and 47%, respectively (p=.02, p<.001, respectively). Three infants required respiratory support; two with COVID-19 (one required oxygen by high-flow nasal cannula for 2 days and one required supplemental oxygen for 2 days); one who was SARS-CoV-2 uninfected required 3 days of non-invasive ventilation and 1 day of oxygen by high flow nasal cannula. Twenty three infants from 2020 were not tested for SARS-CoV-2 (COVID-19 indeterminate) and were excluded from this analysis, but selected demographic factors and clinical parameters are summarized in **Table 4** (available at www.jpeds.com).

The clinical features of the 44 infants in whom a respiratory virus (other than SARS-CoV-2) was detected were compared with the 20 infants with COVID-19 (all of whom had a negative RVP). Of the 44 infants with a positive RVP, 25 were positive for entero/rhinovirus, 2 for respiratory syncytial virus, 2 for entero/rhinovirus as well as respiratory syncytial virus, 7 for influenza A, 1 for influenza B, 5 for parainfluenza, 1 for coronavirus plus 1 for human-metapneumovirus. The infants with COVID-19 were younger (mean age of 29.1 versus 41.1 days, p=.01), more likely to report feeding difficulties (35% versus 21%, p= .001), had a lower mean WBC (7800 versus 10,100 cells/µL, p=.04) and a lower ALC (3200 versus 4800 cells/µL, p=.015) than infants in the respiratory virus group. Three of the

44 [6.8% (95% CI: 2.4, 18.2)] infants with positive RVP had concurrent SBI compared with none of the 20 [0% (95% CI: 0, 16.1)] infants infected with COVID-19 (p=.55).

## Discussion

The key findings of our study are that during the peak of the COVID-19 pandemic in New York, SARS-CoV-2 was the predominant pathogen identified among febrile infants younger than 57 days of age, and the disease was self-limited in all infants with COVID-19. None of the infants infected with SARS-CoV-2 had an additional pathogen identified. Febrile young infants with SARS-CoV-2 infection differ from other febrile infants in that they are younger, are more likely to be lethargic or exhibit feeding difficulties, have lower mean WBC, ANC, and ALC and have a higher likelihood of neutropenia and lymphopenia

Despite performing SARS-CoV-2 testing on only 57% of the 2020 cohort of febrile infants due to limitations on availability of testing during this time, SARS-CoV-2 was detected in 38% of the entire cohort and 67% of those tested. In contrast, although the entire 2020 cohort was tested for other respiratory viruses, a virus was detected in only 15% of febrile infants, similar to a study that demonstrated a decrease in influenza rates while COVID-19 was prevalent and while local school closures and stay-at-home orders were in place.<sup>20</sup> The shutdown of schools and businesses in our community during this time and the resultant decrease in interpersonal contact may have contributed to a lower prevalence of respiratory viruses other than SARS-CoV-2. The larger number of febrile infants seen during 2020 compared with the

Page 11

2018-2019 study periods as well as the high prevalence of SARS-CoV-2 among this cohort attest to the high contagion of SARS-CoV-2 during this time period.

The majority of febrile infants with COVID-19 had a relatively mild infections, with only 2 of 20 infants requiring supplemental oxygen, one of whom also required high flow nasal cannula, findings similar to those described in other case reports and small case series.<sup>8,9,10,11,12</sup> However, severe disease with respiratory failure has been reported in a 4-week-old infant with COVID-19 who was born after a 33-week gestation and in previously healthy infants with COVID-19 who developed pneumonia and evidence of myocardial involvement.<sup>21,22,23</sup>

The significantly higher proportion of infants with SARS-CoV-2 infection of Hispanic ethnicity and with public health insurance compared with SARS-CoV-2 uninfected infants may reflect the more pronounced impact of COVID-19 in Hispanic persons than those of other ethnicities and in persons from lower socioeconomic groups that has been observed in adults.<sup>24,25</sup>

The SARS-CoV-2 infected infants were younger than the SARS-CoV-2 uninfected infants, and were also younger than the subgroup with other respiratory viral infections. This may in part be an artifact of our practice of admitting infants younger than 29 days of age hospital and preferential testing of admitted patients over ambulatory patients. This finding also could reflect the high prevalence of SARS-CoV-2 among women presenting in labor during this pandemic with transmission from the infant's mother or another household member.<sup>26</sup> Infants with COVID-19 presented with lethargy and feeding difficulty more

frequently than their SARS-CoV-2 uninfected counterparts; additionally, feeding difficulty was reported more frequently in infants with COVID-19 than infants infected with other respiratory viruses. The presence of these symptoms may be a useful clue to suspect SARS-CoV-2 infection.

Differences in the CBC results may help to differentiate febrile young infants with SARS-CoV-2 infection as these infants had significantly lower values of WBC, absolute neutrophil count, absolute lymphocyte count, and a higher proportion had neutropenia or lymphopenia compared with febrile infants without SARS-CoV-2 infection. Infants with SARS-CoV-2 infection also had lower WBC and absolute lymphocyte counts compared with the subgroup who had other documented respiratory viral infections. Similarly, Mithal et al reported 2 infants with COVID-19 with a low WBC, Kan et al reported an infant with lymphopenia and neutropenia, and White et al reported 3 infants, all of whom had neutropenia detected during hospitalization.<sup>9,11,27</sup> Although lymphopenia has been observed commonly in adults and older children with COVID-19, neutropenia has not been reported commonly in these older populations. <sup>14,28,29</sup>.

There was a significantly smaller proportion of febrile infants with a SBI during March-April 2020 compared with infants evaluated in March-April 2018 and in March-April 2019, and among infants with SARS-CoV-2 infection compared with those without. The absence of SBI among 20 infants with SARS-CoV-2 infection was notable, because the overall incidence of SBI in febrile infants was 15.2% from 2017 through 2019 at CCMC. (J Leibowitz, unpublished observation). SBI in febrile infants with COVID-19 may be uncommon, similar to findings of

Page 13

low risk of SBI in infants with other viral infections.<sup>30</sup> However, the small sample size precludes conclusions about the risk for SBI in SARS-CoV-2 infected infants. Furthermore, SBI has been reported in infants with COVID-19 by McLaren et al who found a urinary tract infection in 2 of 7 febrile infants with SARS-CoV-2 infection and by Mithal et al who found 1 SBI in 12 infants with SARS-CoV-2 infection among infants younger than 90 days of age. <sup>9,12</sup> The uncommon occurrence of SBI or a second viral pathogen strongly support the assertion that SARS-CoV-2 infection is the cause of the febrile illness in most or all of these infants rather than that detection reflects an asymptomatic infection.

There were several limitations to this study. This was a single center study and findings may not be generalizable. Additionally, as the initial phase of the COVID-19 pandemic in the United States took place in March and April of 2020, we compared febrile infants seen during this time period with febrile infants evaluated in the ED during corresponding months of 2018 and 2019 so generalizability to other time periods is not possible. Lastly, due to variable testing for SARS-CoV-2 at the initial stages of the pandemic, 23 of 53 infants evaluated in the ED because of fever were not tested; therefore we may have underestimated the prevalence of COVID-19 in this patient population during this time period.

SARS-CoV-2 should be considered as a cause of fever in young infants, particularly when the infant has poor feeding and/or lethargy and when leukopenia, lymphopenia, or neutropenia is present. The infection generally is self-limited and has a relatively rapid clinical resolution.

Page 15

## References

1.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. Lancet. 2020;395(10223):497–506.

Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed.
 2020;91(1):157-160.

3. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al. First case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382: 929-936.

4. Kim, L, Whitaker, M, and O'Halloran A, Kambhampati A, Chai SJ, Reingold A et al.
Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020.</li>
MMWR Morb Mortal Wkly Rep. 2020 August 14, 69(32);1081–1088.

5. Bixler D, Miller AD, Mattison CP, Taylor B, Komatsu K, Pompa XP et al. SARS-CoV-2– Associated Deaths Among Persons Aged <21 Years — United States, February 12–July 31, 2020 Morbidity and Mortality Weekly Report, Early Release / Vol. 69 September 15, 2020.

 Dong Y, Mo X, Hu Y, Qi X, Jiang F, Tong S et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020 June;145(6): e20200702. doi:10.1542/peds.2020-0702, Epub online March 16.

7. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S et al.
Coronavirus disease 2019 case surveillance- United States, January 22-May 30, 2020.
MMWR Morb Mortal Wkly Rep. 2020 June 19, 69 (24); 759-765.

8. Robbins E, Ilahi Z, Roth P. Febrile infant: COVID-19 in addition to the usual suspects. Pediatr Infect Dis J. 2020 Jun;39(6):e81-e82.

9.Mithal LB, Machut KZ, Muller WJ, Kociolek LK. SARS-CoV-2 infection in infants less than90 days old. J Pediatr. 2020 Sep;224:150-152.

10.Paret M, Lighter J, Pellett Madan R, Raabe VN, Shust GF, Ratner AJ. SARS-CoV-2 infection (COVID-19) in febrile infants without respiratory distress. Published online ahead of print, 2020 Apr 17. Clin Infect Dis. 2020;ciaa452. doi:10.1093/cid/ciaa452.

11. Kan MJ, Grant LMC, Muña MA, Greenhow TL. Fever without a source in a young infant due to SARS-CoV-2. Published online ahead of print, 2020 Apr 22. J Pediatric Infect Dis Soc. 2020;piaa044. doi:10.1093/jpids/piaa044.

12.McLaren SH, Dayan PS, Fenster DB Ochs JB, Vindas MT, Bugaighis MN, et al. Novel coronavirus infection in febrile infants aged 60 days and younger. Pediatrics. 2020; doi: 10.1542/peds.2020-1550.

13. Feld L, Belfer J, Kabra R, Goenka P, Rai S, Moriarty S et al. A case series of the 2019 Novel
Coronavirus (SARS-CoV-2) in 3 febrile infants in New York. Pediatrics.
2020;146(1):e20201056. doi:10.1542/peds.2020-1056.

14. Kainth MK, Goenka PK, Williamson KA, Fishbein JS, Subramony A, Schleien C et al. Early experience of COVID-19 in a US children' hospital [published online ahead of print, 2020 Jul
17]. Pediatrics. 2020;e2020003186. doi:10.1542/peds.2020-003186.

15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)- A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81.

16. Kelly BT, Tam JS, Routes JM. Screening for severe combined immunodeficiency in neonates. Clin Epidemiol. 2013; 5:363-9.

17. Lanzkowsky P, Lipton JM, Fish JD. Lanzkowsky's Manual of Pediatric Hematology and Oncology 6<sup>th</sup> ed. Amsterdam: Elsevier; 2016.

18.Greenhow TL, Hung YY, Herz AM, Losada E, Pantell RH. The changing epidemiology of serious bacterial infections in young infants. Pediatr Infect Dis J. 2014; 33:595-599.

19. Kuppermann N, Dayan PS, Levine DA, Vitale, M, Tzimenatos, L, Tunik MG. A clinical prediction rule to identify febrile infants 60 days and younger at low risk for serious bacterial infections. JAMA Pediatr. 2019;173(4):342-351.

20. Song X, Delaney M, Shah RK, Campos JM, Wessel DL, Debiasi RL. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children, JAMA Netw Open 2020; 3(9):e2020495. Doi:10.1001/jamanetworkopen.2020.20495.

21. Fraunfelder C, Brierley J, Whittaker E, Perucca G, Bamford A. Infant with SARS-CoV-2 infection causing severe lung disease treated with remdesivir. Pediatrics. 2020; 146(3):e20201701. doi:10.1542/peds.2020-1550.

22. Cui Y, Tian MM, Huang D, Wang X, Huang Y, Fan L et al. A 55 day old female infant infected with COVID 19: presenting with pneumonia, liver injury and heart damage. J Infect Dis. 2020 May 11;221(11):1775-1781.

23. Wardell H, Campbell JI, VanderPluym C, Dixit A. SARS-CoV-2 Infection in Febrile
Neonates [published online ahead of print, 2020 Jul 9]. J Pediatric Infect Dis Soc. 2020;piaa084.
doi:10.1093/jpids/piaa084.

24. Moore JT, Ricaldi JN, Rose CE, Fuld J, Parise M, Kang JG et al. Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5–18, 2020 — 22 States, February–June
2020. MMWR Morb Mortal Wkly Rep. 2020 August 21 69(33);1122–1126.

25. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med. 2020;382(26):2534-2543.

Page 20

26. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020;382(22):2163-2164.

27. White A, Mukherjee P, Stremming J, et al. Neonates Hospitalized with Community-Acquired SARS-CoV-2 in a Colorado Neonatal Intensive Care Unit [published online ahead of print, 2020 Jun 4]. *Neonatology*. 2020;1-5. doi:10.1159/000508962.

28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.23
29.Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. [Epub ahead of print].JAMA Pediatr. 2020 Jun doi:10.100/jamapediatrics.2020.2430

30. Mahajan P, Browne LR, Levine DA Cohen DM, Gattu R, Linakis JG, et al. Risk of bacterial coinfections in febrile infants 60 days old and younger with documented viral infections. J Pediatr. 2018;203:86-91.

		2018 - 2019	)			
	2018	2019	2018-2019	2020	2020 vs 2018-2019,	р
	Number	Number	Number	Number	Risk Difference	
	(%)	(%)	(%)	(%)	(95% CI)	
	N=38	N=33	N=71	N=53		
Mean age, days	33.3	38.8	35.9 (15)	35.3 (14)	0.6	.83
(SD)					(-4.6, 5.7)	
Sex, M	26 (68)	13 (39)	39 (55)	30 (57)	1.7%	1.0
					(-15.7, 18.6)	
Ethnicity-	2 (5)	2 (6)	4 (6)	9/52 (17)	11.7%	.04
Hispanic					(0.4, 24.6)	
Race						
White	17 (45)	10 (30)	27 (38)	22 (42)	3.5%	.08
Black	8 (21)	5 (15)	13 (18)	5 (9)	-9.0%	
Asian	4 (11)	8 (24)	12 (17)	4 (8)	-9.3%	
Multi/Other	9 (24)	10 (30)	19 (27)	20 (38)	11.0%	
Unknown				2 (4)		
Insurance-	22 (58)	13 (39)	35 (49)	33 (62)	13.0%	.2

**Table 1**- Demographics and Clinical Features of Febrile Infants Younger than 57 days: March-April 2018-2019 versus 2020

1 /						
public <sup>1</sup> /no					(-4.6, 29.3)	
insurance						
Admitted to	29 (76)	19 (58)	48 (68)	34 (64)	-3.5%	.7
hospital					(-20.1, 12.9)	
$\overline{\text{RVP}}$ + <sup>2</sup>	14/36	22/32	36/68 (53)	8 (15)	-37.9%	<.001
	(39)	(69)			(-51.3, -21.1)	
SBI present	7 (18)	8 (24)	15 (21)	3 (6)	-15.5%	.02
					(-26.9, -3.0)	

<sup>&</sup>lt;sup>1</sup> Medicaid or Children's Health Insurance Program

<sup>&</sup>lt;sup>2</sup> Tests for Adenovirus, Influenza A, AH1, AH1 2009, AH3, Parainfluenza 1-4, Respiratory Syncytial Virus, Chlamydia pneumoniae, Mycoplasma pneumoniae, Entero/rhinovirus, human-metapneumovirus, coronavirus 229E, HKU1, NL63, OC43

Table 2- Demographics of Febrile Infant	s Younger than 57 d	lays: Comparison by	SARS-CoV-2
Infection Status			

	SARS-CoV-2	SARS-CoV-2	Risk Difference	р
	Infected	Uninfected	(95% CI)	
	Number (%)	Number (%)		
	N=20	N=81		
Mean age, days	29.1 (12)	36.6 (14)	-7.5	.03
(SD)			(-14.4, -0.6)	
Age, $\leq 28$ days	11 (55)	25 (31)	24.1%	.07
			(1.0, 45.3)	
Sex, M	10 (50)	45 (56)	-5.6%	.8
			(-28.1,17.3)	
Race				
White	8 (40)	30 (37)	3.0%	.04
Black	1 (5)	13 (16)	-11.0%	
Asian	0	14 (17)	-17.3%	
Multi-	10 (50)	23(28)	22.6%	
racial/Other				
Unknown	1 (5)	1 (1)	3.8%	
Ethnicity, Hispanic	6 (30)	4 (5)	25.1%	.004
			(8.1, 47.2)	
Insurance, Public/no	16 (80)	39 (48)	31.9%	.01

insurance			(7.7, 47.8)	
Prematurity	3 (15)	4 (5)	10.1%	.14
			(-2.0, 31.3)	
Underlying medical	3 (15)	4(5)	10.1%	.14
condition			(-2.0, 31.3)	

	SARS-CoV-2	SARS-CoV-2	Diale	
	Infected	Uninfected	NISK	n
	Number (%)	Number (%)	(95% CI)	Ρ
	N=20	N=81	(95% CI)	
	Historic	cal Features	0	
Sick contacts		D.	4.4%	
	9(45)	33 (41)	(-17.8, 27.4)	.32
Contact with COVID-				
19	3 (15)	0/10 (0)	15.0%	.53
			(-14.4, 38.0)	
History of cough	1(20)	12 (16)	4.0%	74
	4(20)	13 (16)	(-11.3,_26.5)	./4
History of rhinorrhea	11 (55)	20 (48)	6.9%	62
	11 (55)	39 (48)	(-16.5, 28.7)	.03
History of			30%	
feeding difficulty	13 (65)	21 (26)	(15.0, 57.9)	.002
History of emesis			7.7%	
5	4 (20)	10 (12)	(-7.2, 30.0)	.47
History of diarrhea	0		-7.4%	
	U	6(7)	(-15.2, 9.2)	.0

**Table 3-** Clinical Features of Febrile Infants Younger than 57 days by SARS-CoV-2 Infection

 Status

Lournal Pra nr	
vouling tre pro	

History of irritability	4 (20)	21 (20)	-5.9%	77
	4 (20)	21 (20)	(-21.8, 17.2 <u>)</u>	.//
History of lethargy			21.4%	
	6 (30)	7 (9)	(3.9, 43.7)	.02
History of rash			8.8%	
	3 (15)	5 (6)	(-3.5, 30.2)	.19
	Physica	al Examination	0	
Mean maximum	20.5		-0.1	<b>.</b> .
temperature, Celsius <sup>1</sup>	38.5	38.6	(-0.3, 0.2)	.56
Respiratory distress at	1 (5)		1.3%	1.0
presentation <sup>2</sup>	1 (5)	3 (4)	(-6.5, 20.1)	1.0
Normal auscultatory			2.00/	
lung examination	19 (95)	80 (99)	-3.8%	.36
			(-22.4, 3.1)	
Tachycardia at any	$\mathbf{\mathcal{T}}$			
point in hospital			3.1%	
course <sup>3</sup>	10 (50)	38 (47)	(-197 257)	.81
course			(1).1, 23.1)	
Tachypnea at any point			1.00	
in hospital course <sup>4</sup>	1 (5)	3 (4)	1.3%	1.0
*	. ,		(-6.5, 20.1)	

 <sup>&</sup>lt;sup>1</sup> At home or during hospitalization
 <sup>2</sup> Defined as the presence of tachypnea or retractions
 <sup>3</sup> Defined as heart rate > 180 beats per minute
 <sup>4</sup> Defined as respiration rate > 60 breaths per minute

Lower respiratory tract				
infection <sup>5</sup>	3 (15)	3 (4)	11.3% (-0.5, 32.5)	.09
	Laborator	ry Test Results		
Mean WBC x 10 <sup>9</sup> /L (SD)	7.8 (3.5)	11.2 (5.0)	-3.4 (-5.3, -1.4)	.001
Mean ANC x 10 <sup>9</sup> /L (SD)	2.6 (1.5)	4.4 (3.0)	-1.8 (-2.8, -0.9)	<.001
Mean ALC x 10 <sup>9</sup> /L (SD)	3.2 (1.9)	4.8 (3.2)	-1.6 (-2.7, -0.5)	.005
Neutropenia <sup>6</sup>	4 (20)	2 (2)	17.5% (4.1, 39.2)	.013
Lymphopenia <sup>7</sup>	12 (60)	25 (31)	29.1% (5.3, 49.4)	.02
SBI	0	18 (22)	-22.2% (-32.4, -4.4)	.02
RVP virus detected	0	37/78 (47)	-47.4% (-58.4, – 28.1)	<.001
	Clin	ical Course		
Admission to hospital	15 (75)	56/81 (69)	5.9%	.79

<sup>&</sup>lt;sup>5</sup> Defined as presence of any of the following: abnormal lung exam (crackles, rhonchi or wheeze), hypoxia, parenchymal infiltrate on chest X-ray
<sup>6</sup> Defined as an ANC of < 1.0x10/<sup>9</sup>L
<sup>7</sup> Defined as an ALC of < 3.0x10/<sup>9</sup>L

			(-17.8, 23.4)	
Admission to PICU	1 (5)	1/81 (1)	3.8%	.39
			(-3.1, 22.4)	
Mean hospital	53.4 (15) <sup>9</sup>	61.0 (65) <sup>10</sup>	-7.6	.65
LOS, hrs (SD) <sup>8</sup>			(-41.4, 26.1)	
Required respiratory	2 (10)	1 (1)	8.8%	.1
support				

<sup>&</sup>lt;sup>8</sup> For patients to hospital only
<sup>9</sup> Range 42.2 to 95.3 hours
<sup>10</sup> Range 17.4 to 509.1 hours

	Number (%)	
	N=23	
Mean age (SD)	38.0 (14.6)	
Gender, M	14 (61)	
Ethnicity, Hispanic	3 (13)	
Race:		
White	11 (48)	
Black	4 (17)	
Asian	2 (9)	
Multiracial/other	6 (26)	
Insurance-	13 (57)	
Public/Self-pay		
COVID+ Contact	1 (4)	
RVP +	7 (30)	
SBI detected	0	
Admitted to hospital	11 (48)	

**Table 4- Online** - Demographics of Febrile Infants Younger than 57 days with an IndeterminateSARS-CoV-2 Infection Status